Abstract: A beta-lactamase substrate compound for detection of beta-lactamases, according to formula (I) wherein ? is hydrogen, C1-C16 alkyl, C1-C16 fluoroalkyl or is according to formula (II): wherein X is S or O, and R1 is C1-C16 alkyl, optionally including one or more carbonyl, hydroxyl, ether, ester or carboxyl functional groups; and R is selected from 4-cyanophenyll, 4-nitrophenyl, 4-sulfonephenyl, 2,4-dicyanophenyl, 2-nitro-4-cyanophenyl, 3,4-dinitrophenyl and 3,5-dinitrophenyl. The beta-lactamase substrate compound is hydrolyzable by a beta-lactamase; and the beta-lactamase substrate compound has a degradation at 4° C. equal to or lower than 50% after 4 weeks and equal to or lower than 70% after 18 weeks, and/or a degradation at 20° C. equal to or lower than 80% after 4 weeks and equal to or lower than 85% after 18 weeks. The degradation is determined from the difference of the integration of nuclear magnetic resonance measurement signals of the beta-lactamase substrate compound and of dimethylformamide.

Abstract: A reactive compound is made of modified trimannose-oligosaccharides. Methods are for preparing and using modified trimannose-oligosaccharides. The compounds and methods are for improving the characteristics of a first ligand of interest, especially in therapeutic or diagnostic applications. In particular, a reactive compound includes a trimannose core of formula 1 wherein Man1, Man2 and Man3 moieties are a first, a second and a third mannose, respectively, R1 is a linking group able to bind or binding the GlcNAc group to a first ligand of interest, R2 and R3 are monosaccharides or derivatives thereof, optionally linked to one or more additional saccharide(s). GlcNAz is an unnatural N-Azidoacetylglucosamine group able to bind or binding to a second ligand of interest different from the first ligand of interest.

Abstract: A glycocluster including at least two acetylated-sialic acids covalently linked to a macrocycle, wherein the macrocycle is selected from porphyrins, pillararenes, calixarenes and fullerenes. Each acetylated-sialic acid may be independently selected from 4-O-acetylated-sialic acid, 7-O-acetylated-sialic acid, 8-O-acetylated-sialic acid and 9-O-acetylated-sialic acid. Also a glycocluster for use in the treatment and/or prevention of an infectious disease, such as a coronavirus infection.

Abstract: Compounds having the general formula (I) pharmaceutical compositions containing them for use in inhibiting bacterial heptose biosynthesis and thereby lowering or suppressing bacterial virulence.